Two-Year Primary Patency Rates After Aortoiliac Occlusive Disease Endovascular Treatment

In the last decade, great attention has been paid to endovascular treatment and now it is considered as a treatment of choice in aortoiliac occlusive disease.
To report our 2-year follow-up experience in this field.
Patients and A retrospective review was conducted on patients who underwent aortoiliac angioplasty with or without stenting from September 2013 to March 2015. Medical profile, clinical signs and symptoms, and technical variables of angioplasty were recorded. Technical success rate and primary patency rate were the main outcome measures.
Fifty eight patients (m:f = 53:5) with the mean age of 64.28 ± 10.88 years and the most common initial presentation of intermittent claudication (37.9%) were evaluated. The technical success rate was 100% in each transatlantic inter-society consensus (TASC) subtypes. The mean time of hospital stay was 9.45 ± 7.96 days. The mean follow up period was 14.01 ± 5.87 months (6-27months). The Kaplan-Meier analysis estimated a primary patency rate of TASC subtypes A-D at 1 year as 96.3%, 100%, 66.7%, and 96.3%, respectively. Two years primary patency rates were 96.3%, 100%, 66.7%, and 81.6% for A-D TASC subtypes, respectively. There was no complication or death in the study group.
Endovascular treatment for different TASC II subtypes is associated with considerable technical success rate and primary patency rate even in TASC D, which has been previously indicated to be treated with open surgical procedures.